When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ABBV - Boehringer Ingelheim launches mid-stage study of new CF treatment
AbbVie Inc.
Privately held Boehringer Ingelheim announces the start of enrollment in a Phase 2 clinical trial evaluating different doses of BI 1265162, an epithelial sodium channel inhibitor delivered via the Respimat inhaler, in cystic fibrosis (CF) patients regardless of their mutation status.
More news on: Vertex Pharmaceuticals Incorporated, AbbVie Inc., Proteostasis Therapeutics, Inc., Healthcare stocks news, Stocks on the move,